165 related articles for article (PubMed ID: 32878888)
1. Ionic Strength-Dependent, Reversible Pleomorphism of Recombinant Newcastle Disease Virus.
Rush BS; Djagbare MD; Speir JA; Sanyal G
J Virol; 2020 Oct; 94(22):. PubMed ID: 32878888
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract][Full Text] [Related]
3. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens.
Kanabagatte Basavarajappa M; Kumar S; Khattar SK; Gebreluul GT; Paldurai A; Samal SK
Vaccine; 2014 Jun; 32(28):3555-63. PubMed ID: 24793943
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
8. The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect.
Jung BK; An YH; Jang SH; Jang JJ; Kim S; Jeon JH; Kim J; Song JJ; Jang H
Virol J; 2024 Jan; 21(1):7. PubMed ID: 38178138
[TBL] [Abstract][Full Text] [Related]
9. In vitro infectivity of oncolytic Newcastle Disease Virus: Correlation between plaque and fluorescent focus assays.
Rush BS; Coughlin ML; Sanyal G
J Virol Methods; 2018 Jan; 251():69-74. PubMed ID: 28982603
[TBL] [Abstract][Full Text] [Related]
10. Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid.
Yates JGE; Leacy A; Pham PH; Zielinska N; Tusnadi EA; Susta L; Wootton SK
J Vis Exp; 2022 May; (183):. PubMed ID: 35695536
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.
Tian L; Liu T; Jiang S; Cao Y; Kang K; Su H; Ren G; Wang Z; Xiao W; Li D
Gene Ther; 2023 Feb; 30(1-2):64-74. PubMed ID: 34602608
[TBL] [Abstract][Full Text] [Related]
12. [Rescue of a recombinant Newcastle disease virus expressing the green fluorescent protein].
Ge JY; Wen ZY; Wang Y; Bao ED; Bu ZG
Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):547-51. PubMed ID: 17037052
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.
Cuadrado-Castano S; Ayllon J; Mansour M; de la Iglesia-Vicente J; Jordan S; Tripathi S; García-Sastre A; Villar E
Mol Cancer Ther; 2015 May; 14(5):1247-58. PubMed ID: 25761895
[TBL] [Abstract][Full Text] [Related]
14. Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens.
Bertran K; Lee DH; Criado MF; Balzli CL; Killmaster LF; Kapczynski DR; Swayne DE
Vaccine; 2018 Oct; 36(43):6361-6372. PubMed ID: 30241684
[TBL] [Abstract][Full Text] [Related]
15. [Expressing foreign genes by Newcastle disease virus for cancer therapy].
Bai FL; Tian H; Yu QZ; Renl GP; Li DS
Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249
[TBL] [Abstract][Full Text] [Related]
16. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
17. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus V protein is a determinant of host range restriction.
Park MS; García-Sastre A; Cros JF; Basler CF; Palese P
J Virol; 2003 Sep; 77(17):9522-32. PubMed ID: 12915566
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
20. Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma.
Numpadit S; Ito C; Nakaya T; Hagiwara K
Med Oncol; 2023 Apr; 40(5):138. PubMed ID: 37022566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
